Funding for this research was provided by:
Cancer Research UK (C471 /A15015, C471/A12443)
Health Technology Assessment Programme (12/01/38)
Medical Research Council (MC_UU_12023/24)
Received: 6 October 2020
Accepted: 24 April 2021
First Online: 10 May 2021
: Add-Aspirin was approved by the South Central – Oxford C research ethics committee and is part of the UK National Cancer Research Network (NCRN) portfolio. PATCH was approved by the Leeds (East) Research Ethics Committee.
: Not applicable
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare no support from any organisation for the submitted work; however, MS reports grants from Health Data Research UK, during the conduct of the study; personal fees from Lilly Oncology; personal fees from Janssen; grants and non-financial support from Astellas; grants and non-financial support from Clovis Oncology; grants and non-financial support from Janssen; grants and non-financial support from Novartis; grants and non-financial support from Pfizer; and grants and non-financial support from Sanofi-Aventis, outside the submitted work; FC reports receipt of research grants for the Add-Aspirin trial from Cancer Research UK and the National Institute of Health Research, as well as study drug provision from Bayer Pharmaceuticals. REL reports grants from Cancer Research UK; grants from UK Medical Research Council, during the conduct of the study; and personal fees from Aspirin Foundation, outside the submitted work.